

UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

Program Number	2023 P 1205-7
Program	Prior Authorization/Notification – doxepin cream
Medication	Prudoxin* (doxepin), Zonalon* (doxepin)
P&T Approval Date	12/2016, 12/2017, 12/2018, 1/2020, 3/2021, 3/2022, 3/2023
Effective Date	6/1/2023; Oxford only: 6/1/2023

- 1. Background:**
Prudoxin and Zonalon cream are indicated for the short-term (up to 8 days) management of moderate pruritus in adult patients with atopic dermatitis or lichen simplex chronicus.

2. Coverage Criteria^a:

A. Initial Authorization

1. **Prudoxin* or Zonalon*** will be approved based on the following criteria:

- a. Diagnosis of moderate pruritus due to one of the following:

(1) Atopic dermatitis

-OR-

(2) Lichen simplex chronicus

Initial authorization will be issued for 1 month

B. Reauthorization

1. **Prudoxin* or Zonalon*** will be approved based on both of the following criteria:

- a. Diagnosis of moderate pruritus due to either atopic dermatitis or lichen simplex chronicus

-AND-

- b. Documentation of positive clinical response to therapy

Reauthorization will be issued for 1 month

^a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.

* Brand Prudoxin and Zonalon are typically excluded from coverage.

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits may be in place.

4. References:

1. Prudoxin [package insert]. Ltd. San Antonio, TX: DPT Laboratories, Ltd; June 2017.
2. Zonalon [package insert]. Ltd. San Antonio, TX: DPT Laboratories, Ltd; June 2017.

Program	Prior Authorization/Notification – doxepin cream
Change Control	
Date	Change
12/2016	New program.
12/2017	Annual review with no changes.
12/2018	Annual review. Updated references.
1/2020	Annual review. Updated references.
3/2021	Updated to note brand Zonalon is typically excluded from coverage.
3/2022	Updated to note brand Prudoxin is typically excluded from coverage. Added indication requirement to reauthorization section.
3/2023	Annual review. Added state mandate language.